vTv Therapeutics Inc. (NASDAQ:VTVT) Short Interest Update

Key Points

• Short interest surged by 37.1% to 112,740 shares as of April 15, representing about 3.0% of shares outstanding and a days-to-cover ratio of 2.1.
• Analysts are generally positive with a consensus rating of “Moderate Buy” (five Buys, one Sell) and an average price target of $53.00.
• Shares opened at $29.40 (1‑year range $14–$44) and the company reported quarterly EPS of ‑$0.58, beating estimates of ‑$1.09; market cap is about $115.8M.

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) was the target of a large growth in short interest in April. As of April 15th, there was short interest totaling 112,740 shares, a growth of 37.1% from the March 31st total of 82,236 shares. Based on an average daily trading volume, of 53,225 shares, the days-to-cover ratio is presently 2.1 days. Approximately 3.0% of the shares of the company are short sold.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. TD Cowen assumed coverage on vTv Therapeutics in a report on Monday, January 5th. They issued a "buy" rating for the company. Evercore assumed coverage on vTv Therapeutics in a report on Thursday, March 12th. They issued an "outperform" rating and a $44.00 price objective for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of vTv Therapeutics in a report on Friday, March 27th. Roth Mkm assumed coverage on vTv Therapeutics in a report on Thursday, January 22nd. They issued a "buy" rating and a $58.00 price objective for the company. Finally, Wall Street Zen raised vTv Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, March 14th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $53.00.

vTv Therapeutics Stock Performance

Shares of NASDAQ VTVT opened at $29.40 on Tuesday. The stock has a fifty day moving average price of $36.99 and a two-hundred day moving average price of $33.23. The firm has a market cap of $115.84 million, a P/E ratio of -8.78 and a beta of 0.40. vTv Therapeutics has a 1 year low of $14.00 and a 1 year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last issued its quarterly earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.09) by $0.51. On average, research analysts predict that vTv Therapeutics will post -2.66 earnings per share for the current fiscal year.

Institutional Trading of vTv Therapeutics

A number of hedge funds have recently modified their holdings of VTVT. Goldman Sachs Group Inc. acquired a new position in shares of vTv Therapeutics in the fourth quarter worth $221,000. 683 Capital Management LLC acquired a new position in shares of vTv Therapeutics in the fourth quarter worth $731,000. Geode Capital Management LLC increased its stake in shares of vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock worth $1,128,000 after acquiring an additional 12,896 shares during the last quarter. Finally, Baker BROS. Advisors LP increased its stake in shares of vTv Therapeutics by 52.4% in the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company's stock worth $3,463,000 after acquiring an additional 51,000 shares during the last quarter. Hedge funds and other institutional investors own 17.51% of the company's stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.